Thursday 15 October 2026
Export CGEN’s income statement to Excel — free account
Compugen Ltd.
CGEN Healthcare Biotechnology
Compugen Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $72.8 million, up 161.1% from fiscal 2024. In the quarter to June 2026, revenue grew 107.0%, EPS grew 12.5% and free cash flow fell 155.4%, each against the same quarter a year earlier.
2.08
0.08
+4.00%
Follow CGEN
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
— | — | — | 7 |
| 0.00% | 42.00% | 0.00% | 47.85% | ||
| (24.95%) | 26.03% | 26.68% | 23.86% | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(39.79%) | 28.02% | 30.08% | 32.75% | |
Average Days of Receivables |
149.74 | 11.95 | 11.75 | 20.27 | |
Free Cash Flow per Share |
0.00 | 1.09 | 0.00 | 0.42 | |
Free Cash Flow |
— | 101.69 | — | 40.04 | |
Capital Expenditures |
— | (0.69) | — | (0.69) | |
| Other line items | |||||
Cash ROIC |
0.00% | 40.94% | 0.00% | 18.71% | |
Accounts Receivable Turnover |
2.79 | 28.40 | 26.49 | 22.80 | |
Accounts Payable Turnover |
0.00 | 3.16 | 3.54 | 4.86 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 92.84 | 106.28 | 81.06 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
335.00% | 31.28% | 32.92% | 33.23% | |
Selling, General and Administrative Expense of Revenue |
138.90% | 12.96% | 12.88% | 12.72% | |
Share Based Compensation of Revenue |
0.00% | 10.34% | 0.00% | 8.73% | |
Operating CF/Net income |
0.00 | 2.90 | 0.00 | 1.16 | |
Depreciation/Fixed assets |
0.00 | (0.92) | 0.00 | (1.05) | |
Capex/Depreciation |
— | 1.10 | — | 0.95 | |
Revenue per Share |
0.07 | 0.78 | 0.77 | 0.78 | |
Operating CF per Share |
0.00 | 1.10 | 0.00 | 0.43 | |
Capex per Share |
0.00 | (0.01) | 0.00 | (0.01) | |
Capex to Sales |
0.00 | 0.01 | 0.00 | 0.01 |
Columns are period end dates